Vimizim® (elosulfase alfa)

Vimizim (elosulfase alfa) is covered for treatment of mucopolysaccharidosis type IVA (MPS IVA; Morquio A) and is not supported/covered for other diagnoses. Approval is for 12 months at the recommended dose 2 mg/kg IV once weekly (infused over 3.5–4.5 hours) and requires diagnostic confirmation by deficient N‑acetylgalactosamine‑6‑sulfatase activity or GALNS genetic testing, prescription by or consultation with a geneticist/endocrinologist/metabolic disorder or lysosomal storage disorder specialist, and documentation of applicable safety criteria.

"Vimizim (elosulfase alfa) is indicated for the treatment of individuals with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)."

Sign up to see full coverage criteria, indications, and limitations.